[1]王 静,张虹宇,张 磊,等.动脉灌注化疗联合细胞因子诱导杀伤细胞治疗晚期卵巢癌疗效及对患者血清癌胚抗原、糖类抗原125、可溶性B7-H4蛋白水平的影响[J].陕西医学杂志,2024,(2):199-202,206.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.011]
　WANG Jing,ZHANG Hongyu,ZHANG Lei,et al.Efficacy of arterial infusion chemotherapy combined with CIK in the treatment of advanced ovarian cancer and its effect on serum levels of carcinoembryonic antigen,carbohydrate antigen 125 and soluble B7-H4 protein[J].,2024,(2):199-202,206.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.011]
点击复制

动脉灌注化疗联合细胞因子诱导杀伤细胞治疗晚期卵巢癌疗效及对患者血清癌胚抗原、糖类抗原125、可溶性B7-H4蛋白水平的影响
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年2期
页码:
199-202,206
栏目:
临床研究
出版日期:
2024-02-05

文章信息/Info

Title:
Efficacy of arterial infusion chemotherapy combined with CIK in the treatment of advanced ovarian cancer and its effect on serum levels of carcinoembryonic antigen,carbohydrate antigen 125 and soluble B7-H4 protein
作者:
王 静1; 2; 张虹宇2; 张 磊1; 赵仰光2; 王 健3
(1.天津市肿瘤医院,天津 300060; 2.秦皇岛市第四医院,河北 秦皇岛 066000; 3.河北医科大学第三医院妇产科,河北 石家庄 050000)
Author(s):
WANG Jing; ZHANG Hongyu; ZHANG Lei; ZHAO Yangguang; WANG Jian
(Tianjin Cancer Hospital,Tianjin 300060,China)
关键词:
卵巢癌;  动脉灌注化疗;  细胞因子诱导的杀伤细胞;  癌胚抗原;  糖类抗原125;  可溶性B7-H4蛋白
Keywords:
Ovarian cancer;  Arterial perfusion;  Cytokine induced killer cells;  Carcinoembryonic antigen;  Carbohydrate antigen 125;  Soluble B7-H4 protein
分类号:
R 737.31
DOI:
DOI:10.3969/j.issn.1000-7377.2024.02.011
文献标志码:
A
摘要:
目的:探讨卵巢癌动脉灌注化疗联合细胞因子诱导的杀伤细胞(CIK)治疗晚期卵巢癌疗效及对患者血清癌胚抗原(CEA)、糖类抗原125(CA125)、可溶性B7-H4蛋白(sB7-H4)水平的影响。方法:选择103例晚期卵巢癌患者,随机分为两组,对照组(n=52)行动脉灌注化疗,观察组(n=51)行动脉灌注化疗联合CIK治疗。评价两组患者治疗效果,比较治疗前后卵巢血流参数指标搏动指数(PI)、阻力指数(RI)、收缩期峰值流速(PSV)变化及血清癌胚抗原CEA、CA125、sB7-H4水平变化,随访3年,记录两组患者3年生存率。结果:观察组总有效率88.23%高于对照组的61.54%(P<0.05)。治疗后观察组PI、RI值较对照组升高,RSV值较对照组降低(均P<0.05)。治疗后观察组血清CEA、CA125、sB7-H4水平低于对照组(均P<0.05)。观察组3年生存率为78.43%高于对照组3年生存率为57.69%(P<0.05)。结论:卵巢癌患者行髂内动脉灌注化疗联合CIK治疗是一种安全、有效的治疗手段,但对于化疗中药物的使用及剂量大小仍需进一步研究,以确定选择最优药物和制定最佳治疗方案。
Abstract:
Objective:To investigate the efficacy of arterial infusion chemotherapy combined with cytokine-induced killer cells(CIK)in the treatment of advanced ovarian cancer and its effects on serum levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)and soluble B7-H4 protein(sB7-H4).Methods:A total of 103 patients with advanced ovarian cancer were selected.The control group(n=52)received arterial infusion chemotherapy,and the observation group(n=51)received arterial infusion chemotherapy combined with CIK treatment.The therapeutic effects of the two groups were evaluated,and the changes of ovarian blood flow parameters such as Pulse Index(PI),Resistance Index(RI),peak systolic flow velocity(PSV)and serum carcinoembryonic antigen CEA,CA125 and sB7-H4 levels before and after treatment were compared.The 3-year survival rate of the two groups was recorded.Results:The total effective rate of observation group was 88.23% higher than 61.54% of control group(P<0.05).After treatment,the PI and RI values of the observation group were higher than those of the control group,and the RSV value was lower than that of the control group(all P<0.05).After treatment,the serum CEA,CA125 and sB7-H4 levels in observation group were lower than those in control group(all P<0.05).The 3-year survival rate was 78.43% in the observation group was higher and 57.69% in the control group(P<0.05).Conclusion:The combination of internal iliac artery infusion chemotherapy and CIK is a safe and effective treatment for ovarian cancer patients.However,the use and dosage of chemotherapy drugs need further study to determine the optimal drug selection and formulation of the best treatment plan.

参考文献/References:

[1] 耿海慧,曹爱华.卵巢癌患者多种血清肿瘤标志物表达水平及其对疾病的诊断价值研究[J].陕西医学杂志,2022,51(7):886-889.
[2] SMITH A J B,ALVAREZ R,HEINTZ J,et al.Disparities in biomarker testing in ovarian cancer:A real-world analysis[J].Am J Obstet Gynecol,2023,228(1):98-100.
[3] 李斌,黄蓉,李红霞,等.党黄抗癌汤配合肿瘤细胞减灭术中腹腔热灌注及化疗治疗Ⅳ期上皮性卵巢癌临床研究[J].陕西中医,2019,40(11):1562-1565,1569.
[4] 王雅菲,王健,刘军华.肿瘤细胞减灭术后行腹腔热灌注5-FU+卡铂化疗联合静脉化疗治疗晚期卵巢癌的效果观察[J].中国妇产科临床杂志,2022,23(5):452-454.
[5] 李小丹,郭红燕,李圆.初级与次级预防性使用聚乙二醇化重组人粒细胞集落刺激因子在卵巢癌初始肿瘤细胞减灭术后化疗的价值[J].中国微创外科杂志,2022,22(3):197-201.
[6] ELNAGGAR A C,HADE E M,MALLEY D M,et al.Time to chemotherapy in ovarian cancer:Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center[J].Gynecol Oncol,2018,151(3):501-505.
[7] 方世明,刘玉金,高峰.区域性动脉灌注化疗并栓塞对不能手术的恶性肠梗阻的临床应用[J].介入放射学杂志,2016,25(2):120-124.
[8] 丁劲,曾建勇,刘颖,等.吉西他滨联合顺铂/洛铂髂内动脉化疗栓塞治疗肌层浸润性膀胱尿路上皮癌的疗效观察[J].中国医院用药评价与分析,2022,22(11):1353-1356.
[9] 王怀明.血清AFP、HE4、CA125对卵巢癌早期诊断及病理分期判定的价值[J].中国医学创新,2023,20(2):96-100.
[10] BRATEI A A,STEFAN-VANSTADEN R I,ILIE-MIHAI R M,et al.Simultaneous assay of CA72-4,CA19-9,CEA and CA125 in biological samples using needle three-dimensional stochastic microsensors[J].Sensors(Basel),2023,23(19):8046.
[11] STUCHLIKOVA E,ZAHRADNIKOVA M,NENUTIL R,et al.Asciticka tekutina unadoru vajecníku muze poskytnout informace vhodne pro diagnostiku ascites may provide useful information for diagnosis of ovarian cancer[J].Klin Onkol,2017,30(1):187-190.
[12] REED N,MILLAN D,VERHEIJEN R,等.欧洲肿瘤内科协会对非上皮性卵巢癌的诊断、治疗和随访所制定的临床实践指南[J].国际妇产科学杂志,2011,38(4):339-342.
[13] LUPIA M,MELOCCHI V,BIZZARO F,et al.Integrated molecular profiling of patient-derived ovarian cancer models identifies clinically relevant signatures and tumor vulnerabilities[J].Int J Cancer,2022,151(2):240-254.
[14] BEG A,PARVEEN R,FOUAD H,et al.Identification of driver genes and miRNAs in ovarian cancer through an integrated in-silico approach[J].Biology(Basel),2023,12(2):192.
[15] 张军宪,张鹏,赵昌.术前子宫动脉灌注化疗栓塞术治疗中晚期宫颈癌患者的临床疗效[J].广西医科大学学报,2015,32(6):973-975.
[16] 吴利英,双婷,谢婷婷,等.细胞因子诱导杀伤细胞对卵巢癌细胞耐药的影响[J].现代生物医学进展,2018,18(23):4405-4408
[17] 邓梨平,程瑞文,李平,等.经髂内动脉灌注化疗联合125I粒子植入对宫颈癌根治性放疗后复发的临床观察[J].中南医学科学杂志,2020,48(4):409-412.
[18] 高翔,刘永军,李晓丹,等.细胞因子诱导杀伤细胞联合多西他赛、卡铂治疗晚期卵巢癌的疗效及安全性[J].山东医药,2015,55(5):82-84.
[19] 王琳琳,刘忠杰,蔺春红.Finkler超声评分联合血流阻力指数和HE4对老年卵巢癌患者诊断和化疗疗效评估[J].中国老年学杂志,2023,43(2):279-282.
[20] 苏立贞,孟洁,晋婕.lncRNA H19、VEGF、TSGF在卵巢癌中的表达及与卵巢超声血流参数的相关性[J].检验医学与临床,2022,19(16):2263-2266.
[21] 付小玲,郭哲,唐旭.晚期卵巢癌新辅助化疗中应用紫杉醇联合铂类改良剂量密集型疗法对患者卵巢血流参数、肿瘤标志物水平、生存情况的影响[J].实用癌症杂志,2023,38(4):686-688,693.
[22] 于文亮.卵巢癌患者血清中ROBO4、sB7-H4含量与肿瘤病理特征的相关性研究[J].海南医学院学报,2019,25(11):877-880.
[23] 赵姝娟,张光华,周晓光,等.上皮性卵巢癌患者CT、MRI影像学特征及与血清标志物CEA、CA199、CA125水平的相关性研究[J].现代生物医学进展,2022,22(4):775-780,785.
[24] JOHNSON K M,BRYAN S,GHANBARIAN S,et al.Characterizing undiagnosed chronic obstructive pulmonary disease:A systematic review and meta-analysis[J].Respiratory Research,2018,19(1):26.
[25] 李阿利,吴利英.贝伐珠联合放化疗治疗晚期卵巢癌对患者自然杀伤细胞水平及1年预后的影响[J].医学临床研究,2022,39(11):1747-1750.

相似文献/References:

[1]刘瑞丽,刘小红,李会荣,等.主动循环腹腔热灌注化疗治疗卵巢癌伴腹腔积液效果观察*[J].陕西医学杂志,2019,(12):1630.
　LIU Ruili,LIU Xiaohong,LI Huirong,et al.Curative effect of active circulation intraperitoneal hyperthermic perfusion chemotherapy on ovarian cancer combined with seroperitoneum and its influences on prognosis[J].,2019,(2):1630.
[2]高 燕,杨 红,刘淑娟,等.线粒体动态蛋白在卵巢癌中的表达及临床意义[J].陕西医学杂志,2021,50(12):1589.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.031]
　GAO Yan,YANG Hong,LIU Shujuan,et al.Expression and clinical significance of mitochondrial dynamic protein of 51 kDa in ovarian cancer[J].,2021,50(2):1589.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.031]
[3]段小霞,郭 华,付 婷,等.震颤同系物-5过表达对卵巢癌细胞A2780增殖和凋亡的影响[J].陕西医学杂志,2022,51(5):529.[doi:DOI:10.3969/j.issn.1000-7377.2022.05.004]
　DUAN Xiaoxia,GUO Hua,FU Ting,et al.Effect of quaking homolog-5 overexpression on proliferation and apoptosis of ovarian cancer cell line A2780[J].,2022,51(2):529.[doi:DOI:10.3969/j.issn.1000-7377.2022.05.004]
[4]耿海慧,曹爱华.卵巢癌患者多种血清肿瘤标志物表达水平及其对疾病的诊断价值研究[J].陕西医学杂志,2022,51(7):886.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.029]
　GENG Haihui,CAO Aihua.Expression levels of various serum tumor markers in ovarian cancer patients and their diagnostic value for the disease[J].,2022,51(2):886.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.029]
[5]王 静,张虹宇,张 磊,等.动脉灌注分数联合转化生长因子-β及上皮细胞钙黏蛋白检测对原发性卵巢癌的诊断价值研究[J].陕西医学杂志,2023,52(7):858.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.019]
[6]刘玉锋,薛芳芳.卵巢癌患者造血前B细胞白血病转录因子相互作用蛋白表达和术前中性粒细胞与淋巴细胞比值水平及其临床检测价值[J].陕西医学杂志,2024,(5):662.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.019]
[7]冷小飞,张逸群,魏 峰,等.长链非编码RNA RP11-572P18.1对卵巢癌细胞增殖和侵袭的影响及作用机制实验研究[J].陕西医学杂志,2024,(8):1011.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.001]
　LENG Xiaofei,ZHANG Yiqun,WEI Feng,et al.Effect of long non-coding RNA RP11-572P18.1 on the proliferation and invasion of ovarian cancer cells and its mechanism[J].,2024,(2):1011.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.001]
[8]司 晗,李洁妹,宗佳琪,等.高糖环境对卵巢癌细胞侵袭和迁移的影响及其机制实验研究[J].陕西医学杂志,2024,(8):1016.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.002]
　SI Han,LI Jiemei,ZONG Jiaqi,et al.Effect of high glucose environment on the invasion and migration of ovarian cancer cells and its mechanism[J].,2024,(2):1016.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.002]
[9]王 静,张虹宇,张 磊,等.长链非编码RNA PVT1调控表皮生长因子受体/有丝分裂原活性蛋白激酶通路对卵巢癌细胞的影响实验研究[J].陕西医学杂志,2024,(11):1454.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.003]
　WANG Jing,ZHANG Hongyu,ZHANG Lei,et al.Effect of long non-coding RNA PVT1 on ovarian cancer cells by regulating epidermal growth factor receptor/mitogen-activated protein kinase pathway[J].,2024,(2):1454.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.003]
[10]周佳敏,赵诗杰,朱小兰,等.RNA甲基化修饰在卵巢癌中的作用研究进展[J].陕西医学杂志,2024,(11):1571.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.029]
　ZHOU Jiamin,ZHAO Shijie,ZHU Xiaolan,et al.Research progress on the role of RNA methylation modifications in ovarian cancer[J].,2024,(2):1571.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.029]

备注/Memo

备注/Memo:
基金项目:河北省秦皇岛市科学技术研究与发展计划项目(202101A116)
更新日期/Last Update: 2024-02-05